{"id":116868,"date":"2025-09-29T14:05:25","date_gmt":"2025-09-29T05:05:25","guid":{"rendered":"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/"},"modified":"2025-09-29T14:09:13","modified_gmt":"2025-09-29T05:09:13","slug":"prenatal-testing-usa-japan","status":"publish","type":"post","link":"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en","title":{"rendered":"Current Status of Prenatal Testing in the U.S. \u2014 Differences from Japan and Adoption Rates"},"content":{"rendered":"\n<p>Prenatal genetic testing, particularly <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (non\u2011invasive prenatal testing), is a screening method that uses a pregnant woman\u2019s blood to assess the risk of chromosomal abnormalities in the fetus. Globally, its use is spreading, but in the United States the adoption, regulatory environment, and ethical stance differ notably from Japan. In this article, we compare the U.S. and Japan in terms of the prevalence of <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, institutional differences, and the ethical discourse.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_84 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">\u76ee\u6b21<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#1_Adoption_Rate_and_System_of_NIPT_in_the_US\" >1. Adoption Rate and System of NIPT in the U.S.<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Influence_of_Private_Testing_Companies\" >Influence of Private Testing Companies<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#2_Introduction_and_Restrictions_of_NIPT_in_Japan\" >2. Introduction and Restrictions of NIPT in Japan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#3_Differences_in_What_Is_Checked_Scope_of_Testing\" >3. Differences in What Is Checked \/ Scope of Testing<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#US\" >U.S.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Japan\" >Japan<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#4_Differences_in_Genetic_Counseling\" >4. Differences in Genetic Counseling<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#US_Situation\" >U.S. Situation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Situation_in_Japan\" >Situation in Japan<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#5_Ethical_Social_Backgrounds\" >5. Ethical &amp; Social Backgrounds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#6_Challenges_and_Future_Outlook\" >6. Challenges and Future Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#7_Test_Accuracy_and_Clinical_Interpretation_%E2%80%94_Differences_in_US_vs_Japan\" >7. Test Accuracy and Clinical Interpretation \u2014 Differences in U.S. vs Japan<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#8_Ethical_and_Societal_Impacts_%E2%80%94_Concerns_About_Eugenics\" >8. Ethical and Societal Impacts \u2014 Concerns About Eugenics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#9_Cost_Differences_and_Access_Disparities\" >9. Cost Differences and Access Disparities<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#US_Cost_Structure_Insurance\" >U.S. Cost Structure &amp; Insurance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Japans_Self%E2%80%91Paid_Landscape\" >Japan\u2019s Self\u2011Paid Landscape<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#10_Policy_Future_Trends\" >10. Policy &amp; Future Trends<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Trends_in_the_US\" >Trends in the U.S.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Trends_in_Japan\" >Trends in Japan<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\/#Summary_Lessons_from_Comparing_the_US_and_Japan_on_NIPT\" >Summary: Lessons from Comparing the U.S. and Japan on NIPT<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Adoption_Rate_and_System_of_NIPT_in_the_US\"><\/span>1. Adoption Rate and System of NIPT in the U.S.<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In the U.S., clinical use of <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> began around 2011, and its adoption has accelerated since then. The American College of Obstetricians and Gynecologists (ACOG) revised its guidelines in 2016, recommending that <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> be offered as an option not only to high\u2011risk pregnancies but to all pregnant women. <\/p>\n\n\n\n<p>From 2020 onward, many major U.S. health insurance providers began covering <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> as part of standard prenatal care, which has further driven uptake. <\/p>\n\n\n\n<p>It is estimated that <strong>60\u201380\u202f% of pregnant women in the U.S. who undergo prenatal testing choose <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a><\/strong> (though exact figures vary among regions and insurance plans). <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Influence_of_Private_Testing_Companies\"><\/span>Influence of Private Testing Companies<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In the U.S., several large biotech firms (such as Natera, Illumina, and formerly Sequenom under LabCorp) offer <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>. They engage in active marketing and have established systems allowing pregnant women to order tests online without a direct physician referral. This convenience has supported widespread adoption.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Introduction_and_Restrictions_of_NIPT_in_Japan\"><\/span>2. Introduction and Restrictions of NIPT in Japan<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In Japan, <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> began to be more broadly introduced in 2013. However, even now, it is typically only performed at <strong>certified institutions<\/strong> under the Japan Society of Obstetrics and Gynecology. Many facilities limit eligibility to \u201chigh maternal age\u201d pregnancies (e.g. age 35+) or other risk factors.<\/p>\n\n\n\n<p>In 2022, some facilities expanded eligibility to women in their 20s and early 30s. Still, there is <strong>no public health insurance coverage<\/strong>; the cost is borne entirely by the patient, generally between about \u00a5100,000\u2013\u00a5200,000. This cost barrier creates a significant difference compared to the U.S. model.<\/p>\n\n\n\n<p>Another tension in Japan is between \u201ccertified\u201d and \u201cnon\u2011certified\u201d facilities. There are many non\u2011certified sites that offer <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> without the age restrictions or stringent oversight of certified centers, sometimes conducting counseling and consent processes online. This has raised ethical and regulatory concerns in Japan.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Differences_in_What_Is_Checked_Scope_of_Testing\"><\/span>3. Differences in What Is Checked \/ Scope of Testing<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US\"><\/span>U.S.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In the U.S., many <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> services cover a broader array of chromosomal abnormalities, such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Trisomies 13, 18, 21<\/li>\n\n\n\n<li>Sex chromosome anomalies (e.g. Turner syndrome, Klinefelter syndrome)<\/li>\n\n\n\n<li>Microdeletion syndromes (e.g. 22q11.2 deletion)<\/li>\n<\/ul>\n\n\n\n<p>Some providers are now offering genome\u2011wide <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> (i.e. analysis across a broader range of genetic variants).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Japan\"><\/span>Japan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Many Japanese institutions currently limit testing to the \u201cclassic\u201d trisomies 21, 18, and 13. Many facilities deliberately avoid including sex determination or microdeletion analysis due to ethical caution. The limitation is less a technical one than one of ethical and social consensus in many cases.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Differences_in_Genetic_Counseling\"><\/span>4. Differences in Genetic Counseling<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Situation\"><\/span>U.S. Situation<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In the U.S., genetic counselors are often integrated into the prenatal testing pathway before and after <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>. These professionals are usually certified and are responsible for explaining risks and results in an accessible manner. Some states legally require pretest counseling.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Situation_in_Japan\"><\/span>Situation in Japan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Japan also values genetic counseling, but there is a severe shortage of certified genetic counselors. In practice, physicians or midwives often provide the explanations, leading to variability in the depth of patient understanding, as some critics point out.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"5_Ethical_Social_Backgrounds\"><\/span>5. Ethical &amp; Social Backgrounds<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Social acceptance of prenatal testing is shaped by cultural values and health systems.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S.<\/strong>: There is greater emphasis on \u201cright to know\u201d and reproductive autonomy. Many consider early access to genetic information as a natural choice in prenatal care.<\/li>\n\n\n\n<li><strong>Japan<\/strong>: A cultural default assumption may be \u201cgiving birth\u201d rather than \u201ctesting and selection.\u201d Concerns that prenatal testing may lead to selection or discrimination are stronger, which yields more cautious adoption.<\/li>\n<\/ul>\n\n\n\n<p>These differing value frameworks influence policy design and <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> uptake rates.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"6_Challenges_and_Future_Outlook\"><\/span>6. Challenges and Future Outlook<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>As <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> becomes more accessible globally, Japan is likely to see further liberalization and technological innovation, but it will face several challenges:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Institutional setup: creating a regulatory and reimbursement framework<\/li>\n\n\n\n<li>Information provision: expanding quality genetic counseling<\/li>\n\n\n\n<li>Ethical debate: establishing rules to prevent discriminatory use of genetic data<\/li>\n<\/ul>\n\n\n\n<p>In the U.S., concerns already arise about \u201coverdiagnosis\u201d and false positives, which can lead to anxiety or unnecessary invasive follow\u2011ups. Balancing technical reliability with psychological support remains an ongoing issue.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"7_Test_Accuracy_and_Clinical_Interpretation_%E2%80%94_Differences_in_US_vs_Japan\"><\/span>7. Test Accuracy and Clinical Interpretation \u2014 Differences in U.S. vs Japan<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Though <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is widely considered a \u201chigh\u2011accuracy screening test,\u201d it is not a diagnostic test. ACOG emphasizes that a positive result must be confirmed via invasive diagnostic testing (e.g. amniocentesis). <\/p>\n\n\n\n<p>In the U.S., sensitivity and specificity data for trisomy 21 are often reported around 99.3\u202f% sensitivity, and specificity near 99.9\u202f%. <\/p>\n\n\n\n<p>In practice, when the tested population is low risk, the positive predictive value declines. Thus, the U.S. guidelines continue to stress confirmatory testing for positive results. <\/p>\n\n\n\n<p>In Japan, though the precision of <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is respected, concerns have been raised over misinterpretation, anxiety, or decision-making based solely on a positive result. Some pregnancies have been terminated prematurely without confirmatory testing. This highlights the necessity for better information and support.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"8_Ethical_and_Societal_Impacts_%E2%80%94_Concerns_About_Eugenics\"><\/span>8. Ethical and Societal Impacts \u2014 Concerns About Eugenics<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Widespread use of prenatal testing brings forward fears that disabled lives might be undervalued and that social pressure towards \u201cnon\u2011disabled births\u201d may intensify.<\/p>\n\n\n\n<p>In Japan, there is greater societal sensitivity around the idea that prenatal testing might steer toward \u201cselection of life.\u201d Medical societies and institutions often incorporate stricter ethical guidelines, and many limit the scope of testing intentionally to reduce this risk.<\/p>\n\n\n\n<p>In the U.S., this discussion is often framed under \u201creproductive rights,\u201d emphasizing a woman\u2019s autonomy, but advocacy groups for people with disabilities are vocal in critiquing how such testing can influence social expectations.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full\"><img decoding=\"async\" width=\"640\" height=\"427\" src=\"\/nipt\/wp-content\/uploads\/2025\/09\/30646636_s.webp\" alt=\"\u598a\u5a66\" class=\"wp-image-116719\"\/><\/figure><\/div>\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"9_Cost_Differences_and_Access_Disparities\"><\/span>9. Cost Differences and Access Disparities<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"US_Cost_Structure_Insurance\"><\/span>U.S. Cost Structure &amp; Insurance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In the U.S., many private insurers now cover <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a>, and out-of-pocket costs for insured patients often range from zero to a few hundred U.S. dollars, depending on plan. However, uninsured individuals or those with limited coverage still face barriers, presenting a disparity in access tied to socioeconomic status. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Japans_Self%E2%80%91Paid_Landscape\"><\/span>Japan\u2019s Self\u2011Paid Landscape<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In Japan, <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> is entirely elective and paid out-of-pocket. The cost is typically between \u00a590,000 and \u00a5200,000, depending on the facility. Because there\u2019s no insurance coverage, cost becomes a major factor limiting access and creating inequalities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"10_Policy_Future_Trends\"><\/span>10. Policy &amp; Future Trends<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trends_in_the_US\"><\/span>Trends in the U.S.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In 2022, the FDA initiated reexamination of the accuracy and marketing methods of some <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> products, signaling possible future regulatory tightening. Also, the integration of AI and enhanced genomic analytics is being explored.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Trends_in_Japan\"><\/span>Trends in Japan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In Japan, in 2023 the Ministry of Health, Labour and Welfare convened meetings to discuss the status of \u201cnon\u2011certified facilities.\u201d There is speculation that by 2025 some partial insurance coverage for <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> might be considered. Still, institutional reform is slow, so for now the practice remains nonuniform across facilities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary_Lessons_from_Comparing_the_US_and_Japan_on_NIPT\"><\/span>Summary: Lessons from Comparing the U.S. and Japan on NIPT<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>When comparing the U.S. and Japan, the differences in <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/\">NIPT<\/a> adoption, institutional frameworks, and ethical perspectives are striking. The U.S. tends to emphasize freedom, accessibility, and flexibility, while Japan leans toward cautious incrementalism and stronger ethical oversight.<\/p>\n\n\n\n<p>Neither system is perfect. Each reflects cultural values, social structures, and medical norms. The key is not which is \u201cbetter,\u201d but how each society can develop a system that aligns with its values and ensures that prenatal testing is used ethically, equitably, and with dignity.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"Prenatal genetic tes&#8230;\n <a href=\"https:\/\/www.hiro-clinic.or.jp\/nipt\/prenatal-testing-usa-japan\/?lang=en\">\u7d9a\u304d\u3092\u8aad\u3080<\/a>","protected":false},"author":122,"featured_media":116864,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[97],"tags":[],"class_list":["post-116868","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/users\/122"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/comments?post=116868"}],"version-history":[{"count":2,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116868\/revisions"}],"predecessor-version":[{"id":116871,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/posts\/116868\/revisions\/116871"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media\/116864"}],"wp:attachment":[{"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/media?parent=116868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/categories?post=116868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hiro-clinic.or.jp\/nipt\/wp-json\/wp\/v2\/tags?post=116868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}